This is publication #65 of the HALT-C Trial.
Version of Record online: 7 APR 2011
Copyright © 2011 American Association for the Study of Liver Diseases
Volume 53, Issue 4, pages 1100–1108, April 2011
How to Cite
Di Bisceglie, A. M., Stoddard, A. M., Dienstag, J. L., Shiffman, M. L., Seeff, L. B., Bonkovsky, H. L., Morishima, C., Wright, E. C., Snow, K. K., Lee, W. M., Fontana, R. J., Morgan, T. R., Ghany, M. G. and for the HALT-C Trial Group (2011), Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon . Hepatology, 53: 1100–1108. doi: 10.1002/hep.24169
Conflicts of Interest: Financial relationships of the authors with Hoffmann-La Roche, Inc. (now Genentech), are as follows: A.M. Di Bisceglie is a consultant and receives research support; M.L. Shiffman is a consultant on the speaker's bureau and receives research support; W.M. Lee receives research support; R.J. Fontana is on the speaker's bureau; and T.R. Morgan receives research support.
Dr. Stoddard owns stock in Johnson & Johnson, Bristol-Myers Squibb, and Proctor and Gamble.
Dr. Bonkovsky consults for and advises Boehringer-Ingelheim and Novartis and received grants from Novartis and Vertex.
Dr. Morishima consults for Vertex and Merck.
Dr. Morgan received grants from Merck, Genentech, and Vertex. He consults for and advises Vertex.
- Issue online: 7 APR 2011
- Version of Record online: 7 APR 2011
- Accepted manuscript online: 11 JAN 2011 12:24PM EST
- Manuscript Accepted: 23 DEC 2010
- Manuscript Received: 17 NOV 2010
- National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK contract numbers are listed in the Appendix)
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Cancer Institute; the National Center for Minority Health and Health Disparities
- General Clinical Research Center and Clinical and Translational Science Center grants from the National Center for Research Resources, National Institutes of Health (NIH grant numbers are listed in the Appendix)
- Intramural Research Program of the NIH, NIDDK
- Hoffmann-La Roche, Inc.